SLC5A2 and stage 5 chronic kidney disease: Dapagliflozin, canagliflozin, ertugliflozin, and empagliflozin are the four SGLT2 inhibitors approved by the US Food Drug Administration.14 SGLT2 inhibitors have potential benefits such as reduced cardiovascular risk and prevention of end-stage renal disease.